22 withdrawn. 22 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 22 | Withdrawn 22 |
| Phase 1 | 1 | Withdrawn 1 |
Follow Ct: new trials by email Literature Review of Ct trials Research Report on Ct
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Comparing 123I-MIBG and 18F-MFBG Imaging in Patients With Newly Diagnosed, High Risk Neuroblastoma Biospecimen Collection, Computed Tomography, Florbenguane F18 - Ganglioneuroblastoma, Ganglioneuroblastoma, Nodular | Phase 2 | Withdrawn | Children's Oncology Group | 2026-09-22 | 2026-09-16 | |
| Photoimmunotherapy With ASP-1929 and Cemiplimab for the Treatment of Refractory, Inoperable, and Metastatic Stage IIIB-IV Non-small Cell Lung Cancer Biospecimen Collection, Cemiplimab, Cetuximab Sarotalocan Sodium - Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma | Phase 2 | Withdrawn | Roswell Park Cancer Institute | 2026-08-15 | 2026-09-15 | |
| RP2 and Tivozanib for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy Biopsy Procedure, Biospecimen Collection, Computed Tomography - Advanced Clear Cell Renal Cell Carcinoma, Advanced Renal Cell Carcinoma | Phase 2 | Withdrawn | City of Hope Medical Center | 2026-08-11 | 2026-10-01 | |
| Axatilimab Plus Standard of Care Therapy for the Prevention of Graft Versus Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematologic Cancer, ABRAXAS Trial Allogeneic Hematopoietic Stem Cell Transplantation, Axatilimab, Biospecimen Collection - Hematopoietic and Lymphatic System Neoplasm | Phase 2 | Withdrawn | Mayo Clinic | 2026-06-01 | 2026-09-03 | |
| CBX-12 for the Treatment of Metastatic Chemotherapy-Refractory Microsatellite Stable Colorectal Cancer Biopsy Procedure, Biospecimen Collection, Computed Tomography - Metastatic Mismatch Repair Proficient Colorectal Carcinoma, Refractory Mismatch Repair Proficient Colorectal Carcinoma | Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2026-02-17 | 2025-10-06 | |
| Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian Cancer Bevacizumab, Biospecimen Collection, Computed Tomography - Platinum-Refractory Fallopian Tube Carcinoma, Platinum-Refractory Ovarian Carcinoma | Phase 1 / Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2025-10-31 | 2025-06-03 | |
| Pembrolizumab With Androgen Deprivation Therapy and Radiotherapy for the Treatment of Patients With High Risk Localized Prostate Cancer Gonadotropin Releasing Hormone Agonists and Antagonists, Bicalutamide, Biopsy Procedure - High Risk Prostate Carcinoma, Localized Prostate Adenocarcinoma | Phase 2 | Withdrawn | OHSU Knight Cancer Institute | 2025-04-16 | 2025-09-23 | |
| Cemiplimab for the Treatment of Untreated Brain Metastases From PD-L1 >= 50% Non-Small Cell Lung Cancer Biospecimen Collection, Cemiplimab, Computed Tomography - Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain | Phase 2 | Withdrawn | City of Hope Medical Center | 2025-04-15 | 2025-05-26 | |
| Dendritic Cell-Based Treatment Plus Immunotherapy for the Treatment of Metastatic or Unresectable Triple Negative Breast Cancer Alpha-type-1 Polarized Dendritic Cells, Biopsy, Computed Tomography - Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8 | Phase 2 | Withdrawn | Roswell Park Cancer Institute | 2025-02-01 | 2025-01-29 | |
| Botensilimab, Balstilimab and Regorafenib or Botensilimab and Balstilimab for the Treatment of Advanced or Metastatic Microsatellite Stable Colorectal Cancer Balstilimab, Biopsy, Biospecimen Collection - Advanced Colon Adenocarcinoma, Advanced Colorectal Adenocarcinoma | Phase 2 | Withdrawn | City of Hope Medical Center | 2024-11-01 | 2024-11-21 | |
| Adding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL) Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - T Acute Lymphoblastic Leukemia, T Lymphoblastic Lymphoma | Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2024-08-09 | 2024-05-17 | |
| Onvansertib in Combination With Gemcitabine and Nab-paclitaxel for the Treatment of Patients With Locally-advanced, Unresectable, or Metastatic Pancreatic Ductal Adenocarcinoma Onvansertib, Gemcitabine, Nab-paclitaxel - Locally Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma | Phase 2 | Withdrawn | OHSU Knight Cancer Institute | 2024-08-01 | 2024-07-19 | |
| Testing the Addition of an Investigational Drug, Xevinapant, to Usual Radiation Therapy Plus Cisplatin/Carboplatin for Patients With Head and Neck Cancer Biospecimen Collection, Carboplatin, Chest Radiography - Head and Neck Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma | Phase 2 | Withdrawn | ECOG-ACRIN Cancer Research Group | 2024-04-12 | 2024-07-25 | |
| Venetoclax, Rituximab and Nivolumab in Combination for the Treatment of Richter's Transformation Arising From Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Biopsy, Biospecimen Collection, Bone Marrow Biopsy - Recurrent Transformed Chronic Lymphocytic Leukemia, Refractory Transformed Chronic Lymphocytic Leukemia | Phase 2 | Withdrawn | Northwestern University | 2024-03-29 | 2024-02-29 | |
| Olaparib and Alpelisib for Treatment of Metastatic Breast Cancer, A ComboMATCH Treatment Trial Alpelisib, Biopsy, Biospecimen Collection - Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8 | Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2023-10-23 | 2024-03-20 | |
| Testing Anti-Cancer Drugs Erdafitinib With or Without Atezolizumab in Patients With Localized Bladder Cancer Not Able to Receive Cisplatin Chemotherapy, NERA Trial Atezolizumab, Biospecimen Collection, Computed Tomography - Bladder Carcinoma, Bladder Urothelial Carcinoma | Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2023-10-12 | 2025-10-21 | |
| Gallium-68 PSMA-11 PET in Participants With Prostate Cancer Computed Tomography, Gallium Ga 68-labeled PSMA-11, Magnetic Resonance Imaging - Metastatic Prostate Carcinoma, Recurrent Prostate Carcinoma | Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2022-09-26 | 2024-03-07 | |
| Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum Resistant Ovarian Cancer That Has Progressed Through PARP Inhibitor Therapy Computed Tomography, Copanlisib Hydrochloride, Magnetic Resonance Imaging - Platinum-Refractory Fallopian Tube Carcinoma, Platinum-Refractory Ovarian Carcinoma | Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2022-06-30 | 2023-09-26 | |
| Testing Nivolumab and BMS-986016 (Relatlimab) as Potentially Targeting Treatment in Cancers That Are LAG-3+ and Have Mismatch Repair Deficiency (MATCH - Subprotocol Z1M) Biopsy, Biospecimen Collection, Computed Tomography - Advanced Lymphoma, Advanced Malignant Solid Neoplasm | Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2022-02-22 | 2024-05-06 | |
| Robotic Bronchoscopy With Cone CT and Indocyanine Green to Aid Removal of Lung Lesions in Patients With Stage I Non-small Cell Lung Cancer or Lung Metastases, REPLACING Study Computed Tomography, Indocyanine Green Solution, Therapeutic Bronchoscopy - Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Lung | Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2022-01-26 | 2024-10-23 |
Showing 20 of 22. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (5) · Lung Neoplasms (4) · Colorectal Neoplasms (2) · Prostatic Neoplasms (2) · Brain Neoplasms (1) · Carcinoma (1) · Carcinoma, Renal Cell (1) · Carcinoma, Transitional Cell (1) · Clear-cell metastatic renal cell carcinoma (1) · Colonic Neoplasms (1) · Ganglioneuroblastoma (1) · Hypopharyngeal Neoplasms (1) · Laryngeal Neoplasms (1) · Lymphoma (1) · Mouth Neoplasms (1)
National Cancer Institute (NCI) (8) · City of Hope Medical Center (3) · ECOG-ACRIN Cancer Research Group (2) · M.D. Anderson Cancer Center (2) · OHSU Knight Cancer Institute (2) · Roswell Park Cancer Institute (2) · Children's Oncology Group (1) · Mayo Clinic (1) · Northwestern University (1)
United States (11)
Arthur Hung (1) · Arya Amini (1) · Chaoyuan Kuang (1) · Charles B Nguyen (1) · Charles D Lopez (1) · David W Rice (1) · Di Maria Jiang (1) · Gerburg M Wulf (1) · Gregory C Ravizzini, MD (1) · Heath D Skinner (1) · Kristen M O'Dwyer (1) · Kristen P Zeligs (1) · Leora Horn (1) · Marwan G Fakih (1) · Nilofer S Azad (1)
P30CA033572 (3), U10CA180820 (3), U10CA180868 (2), U10CA180888 (2), P30CA060553 (1), U10CA180821 (1), UM1CA186644 (1), UM1CA186690 (1), UM1CA228823 (1)